Teva's new drugs offset generic losses, lifting margins and the 2026 outlook
Teva's third-quarter revenue fell 2%, but growth in innovative medicines lifted non-GAAP margin and adjusted EBITDA, and the 2026 guidance was raised.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Teva's revenue in the third quarter fell 2%. Still, growth in innovative medicines helped lift the non-GAAP margin and adjusted EBITDA.
The company raised its 2026 guidance, citing momentum from AUSTEDO, UZEDY and AJOVY. The decline in generic Revlimid sales remains the main factor holding back results.
why it matters
For investors, the key point is that growth in newer drugs currently outweighs losses from generics, and the higher guidance may support interest in Teva shares and the pharma sector.
market impact
Teva shares: higher guidance and better margins support interest in the stock
- Teva shares pressure up — higher guidance and better margins support investor interest
tags
instruments
sources
- TEVA: Innovative growth lifts margins and guidance despite generic erosion — TradingView, 3 November 2026 at 12:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗